3 Stocks Pushing The Health Care Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 16,929 as of Tuesday, June 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 966 issues advancing vs. 1,989 declining with 165 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the sector include CR Bard ( BCR), down 3.9%, Jazz Pharmaceuticals ( JAZZ), down 3.6%, Actavis ( ACT), down 1.7%, Biogen Idec ( BIIB), down 1.6% and Regeneron Pharmaceuticals ( REGN), down 1.6%. Top gainers within the sector include Illumina ( ILMN), up 1.4%, Bristol-Myers Squibb Company ( BMY), up 0.7%, Teva Pharmaceutical Industries ( TEVA), up 0.6% and Gilead ( GILD), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Eli Lilly and ( LLY) is one of the companies pushing the Health Care sector lower today. As of noon trading, Eli Lilly and is down $0.58 (-1.0%) to $59.16 on light volume. Thus far, 1.3 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.8 million shares. The stock has ranged in price between $59.09-$59.82 after having opened the day at $59.82 as compared to the previous trading day's close of $59.74.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $66.8 billion and is part of the drugs industry. Shares are up 17.1% year-to-date as of the close of trading on Monday. Currently there are 5 analysts that rate Eli Lilly and a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Express Scripts ( ESRX) is down $0.38 (-0.5%) to $71.28 on light volume. Thus far, 1.5 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.5 million shares. The stock has ranged in price between $71.18-$71.50 after having opened the day at $71.37 as compared to the previous trading day's close of $71.67.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. The company offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $55.2 billion and is part of the health services industry. Shares are up 2.0% year-to-date as of the close of trading on Monday. Currently there are 14 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Express Scripts Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Valeant Pharmaceuticals International ( VRX) is down $2.13 (-1.7%) to $124.50 on average volume. Thus far, 1.3 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $124.37-$127.87 after having opened the day at $126.44 as compared to the previous trading day's close of $126.63.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $42.7 billion and is part of the drugs industry. Shares are up 7.9% year-to-date as of the close of trading on Monday. Currently there are 11 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and disappointing return on equity. Get the full Valeant Pharmaceuticals International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists